Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

Introduction Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are associated with a progressive loss of lung function and a poor prognosis. Treatment with antifibrotic agents can slow, but not halt, disease progression, and treatment disconti...

Full description

Saved in:
Bibliographic Details
Main Authors: Jeffrey J Swigris, Toby M Maher, Tamera J Corte, Aryeh Fischer, Hong Xiao, Lisa Lancaster, Takafumi Suda, Xiaojiang Zhan, Jonathan G Goldin, Scott M Palmer, Hideaki Watanabe, Takashi Ogura, Anne Minnich, Giridhar S Tirucherai, Brandon Elpers, R Adam Smith, Edgar D Charles
Format: Article
Language:English
Published: BMJ Publishing Group 2021-01-01
Series:BMJ Open Respiratory Research
Online Access:https://bmjopenrespres.bmj.com/content/8/1/e001026.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopenrespres.bmj.com/content/8/1/e001026.full

Similar Items